PE firm's £459m capital fund invests in growing CRO

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: CRO, Private equity, expansion, Investment, operations, facility, Drug development

The UK-based private equity firm CBPE has purchased a majority stake in Simbec-Orion and will expand the CRO's reach both geographically and across all business units.

A Simbec-Orion spokesperson told us the company wanted to create a platform for growth, and the option presented by CBPE provided the opportunity for “the management team to remain and take the company forward."

In addition to the investment in shares, CBPE has committed funds for future investment in operations, facilities, and expansion. CBPE expressed its intent to pursue expansion of Simbec-Orion geographically into the US, continental Europe, and across all its business units, including early Phase I-III studies, central laboratory studies, and drug development consulting. 

Simbec Research and Orion Clinical merged in 2014 to become Simbec-Orion. This merger was funded by the Wales Life Sciences Investment Fund (WLSIF).

Ronald Openshaw, CEO of Simbec-Orion said in a statement, “The combination of Simbec Research and Orion Clinical provided the base to create a growing CRO in the mid-market. We created a strategy for a clearly defined and differentiated offering where our people can use their excellence, commitment and passion to improve patient’s lives.

"We are delighted to secure this return for the WLSIF and have clear plans with CBPE for the future growth of the Group.”

Since 2014, Simbec-Orion has seen revenue increase from £13.2m to more than £30m for the year ending December 31, 2018.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more